
Lannett Company LCI
Quarterly report 2023-Q1
added 05-15-2023
Lannett Company General and Administrative Expenses 2011-2026 | LCI
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 81 M | 68.1 M | 79.5 M | 87.6 M | 82.2 M | 73.5 M | 68.3 M | 49.5 M | 38.6 M | 22.4 M | 20.2 M | 15.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 87.6 M | 15.9 M | 57.2 M |
Quarterly General and Administrative Expenses Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.4 M | 18.3 M | 16.7 M | 35 M | 17.6 M | 18.8 M | 18.9 M | 37.7 M | 17.6 M | 13.7 M | 15.1 M | 13.7 M | 15.1 M | 17.4 M | 21.3 M | 17.4 M | 21.3 M | 23.2 M | 20.6 M | 23.2 M | 20.6 M | 28.5 M | 19 M | 28.5 M | 19 M | 18.1 M | 21.3 M | 18.1 M | 21.3 M | 14.7 M | 15.5 M | 14.7 M | 15.5 M | 10.8 M | 10.5 M | 12.8 M | 10.6 M | 9.89 M | 7.18 M | 9.89 M | 7.18 M | 5.16 M | 6.17 M | 5.16 M | 6.17 M | 4.42 M | 4.74 M | 4.42 M | 4.74 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 37.7 M | 4.42 M | 15.9 M |
General and Administrative Expenses of other stocks in the Drug manufacturers industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
7.48 M | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
69 M | $ 18.79 | 0.99 % | $ 120 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
13.2 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
138 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
935 M | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
14.4 M | - | - | $ 50.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
11.1 M | $ 3.12 | 1.63 % | $ 43.9 M | ||
|
Endo International plc
ENDP
|
568 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
12.2 M | - | - | $ 36.6 M | ||
|
Agile Therapeutics
AGRX
|
10.5 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
18.5 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
44.9 M | - | -23.39 % | $ 1.76 M | ||
|
Cronos Group
CRON
|
95.9 M | $ 2.56 | 1.59 % | $ 1.33 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
181 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
35.7 M | - | - | $ 33.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
390 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
58.2 M | - | 2.45 % | $ 38.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
28.3 M | - | - | $ 193 M | ||
|
Bausch Health Companies
BHC
|
2.92 B | $ 5.4 | 2.57 % | $ 1.97 B | ||
|
Harrow Health
HROW
|
153 M | $ 36.41 | 2.75 % | $ 1.34 B | ||
|
Aurora Cannabis
ACB
|
119 M | $ 3.45 | 2.38 % | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
170 M | $ 1.02 | 3.25 % | $ 110 M | ||
|
PetIQ
PETQ
|
196 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
34.4 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
131 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
21 M | - | -4.76 % | $ 65.3 M | ||
|
Eagle Pharmaceuticals
EGRX
|
107 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
295 M | $ 2.47 | 9.38 % | $ 325 M | ||
|
Evolus
EOLS
|
221 M | $ 4.13 | 1.23 % | $ 266 M | ||
|
OrganiGram Holdings
OGI
|
12.8 M | $ 1.41 | 2.55 % | $ 402 M | ||
|
Emergent BioSolutions
EBS
|
368 M | $ 8.34 | 5.97 % | $ 427 M | ||
|
Pacira BioSciences
PCRX
|
294 M | $ 23.17 | 2.84 % | $ 1.07 B | ||
|
Sundial Growers
SNDL
|
38.4 M | $ 1.37 | 4.2 % | $ 3.37 M | ||
|
Tilray
TLRY
|
165 M | $ 6.8 | 5.19 % | $ 4.2 B | ||
|
Solid Biosciences
SLDB
|
38.9 M | $ 7.92 | 2.33 % | $ 693 M | ||
|
Veru
VERU
|
31.2 M | $ 2.54 | 2.42 % | $ 343 M | ||
|
Viatris
VTRS
|
4.07 B | $ 13.63 | 3.57 % | $ 16.4 B | ||
|
OptiNose
OPTN
|
79.8 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
40 M | - | -27.8 % | $ 2.56 M | ||
|
Relmada Therapeutics
RLMD
|
32.2 M | $ 6.9 | 2.22 % | $ 272 M | ||
|
Rockwell Medical
RMTI
|
14 M | $ 0.94 | -0.61 % | $ 33.8 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.36 M | $ 2.31 | 4.52 % | $ 2.87 M | ||
|
SCYNEXIS
SCYX
|
14.4 M | $ 0.95 | -0.77 % | $ 47.4 M | ||
|
Zomedica Corp.
ZOM
|
24.5 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
14.2 M | - | - | $ 55.5 M | ||
|
Tricida
TCDA
|
37.6 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
2.45 M | $ 0.61 | 0.11 % | $ 2.62 M | ||
|
TherapeuticsMD
TXMD
|
6.85 M | $ 2.13 | 5.69 % | $ 24.6 M |